Related Experiment Video
Updated: Jul 18, 2026
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Oral but not transdermal estrogen replacement therapy reduced level of tissue factor pathway inhibitor: cross-over
Tomas Fait1, Michal Vrablik, David Cibula
1Department of Obstetrics and Gynaecology, General Faculty Hospital Prague and 1st Faculty of Medicine, Charles University, Czech Republic. tfait@seznam.cz
Objectives:
The purpose of the present study was to determine changes of biochemical risk factors of thromboembolism especially of TFPI during the use of oral versus transdermal administration of early estrogen replacement therapy.
Methods:
In a 12-week prospective, randomized, cross-over trial, oestradiol was administered orally in a dose of 2 mg daily or transdermally in an equivalent dose of 0.05 mg daily. Forty-five healthy early postmenopausal women were included into the study within 12 weeks after the hysterectomy and ovariectomy (surgical castration). Forty-one women completed the study and their data were analyzed. The average age was of 49+/- 6 years.
Results:
After an oral therapy, the average value of TFPI decreased significantly (p < 0.0001) from 87.5 +/- 38.5 ng/ml to 68 +/- 37 ng/ml but remained stable in transdermal group (81.9 +/- 36.8 ng/ml). No significant changes occurred in D-dimers. In both groups AT-III and fibrinogen decreased without exceeding their physiological ranges.
Conclusions:
The oral therapy reduced significantly TFPI levels compared to transdermal route of administration. The results confirm more pronounced impact of oral estrogen on hemostasis variables.
Related Concept Videos
01:18Transdermal Drug Delivery Systems
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...